Pear therapeutics secures US$400M in deal that will see it merge with Thimble Point Acquisition Corporation

US – Pear Therapeutics is set to merge with special purpose acquisition company (SPAC) Thimble Point Acquisition Corp as it is set to land a spot on the Nasdaq Stock Exchange. The deal will give the developer of the first three FDA-authorized prescription digital therapeutics (PDTs) around $400 million to support its growth plans. Pear helped put PDTs on the map in 2017 and 2018, when it won FDA approval for substance-use disorder app Reset, landed a co-promotion deal with Sandoz, struck a development agreement with Novartis and raised a…

Read More